Key clinical point: Women with heart failure with reduced ejection fraction may need only half the recommended doses of common drugs.

Major finding: Women reached the highest level of drug efficacy at half the doses of ACE inhibitors or angiotensin-receptor blockers and beta-blockers needed by men to reach the same level.

Study details: An ad hoc analysis of a prospective study of 1,308 men and 402 women with heart failure with reduced ejection fraction in 11 European countries.

Disclosures: The European Commission funded the study. Several study authors reported various disclosures.